Exelixis (NASDAQ:EXEL) EVP Patrick Haley Sells 28,043 Shares

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick Haley sold 28,043 shares of the firm’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $42.58, for a total transaction of $1,194,070.94. Following the completion of the transaction, the executive vice president directly owned 374,029 shares in the company, valued at approximately $15,926,154.82. This represents a 6.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Exelixis Price Performance

EXEL stock traded down $0.26 during trading on Monday, reaching $42.25. 3,975,801 shares of the company were exchanged, compared to its average volume of 2,953,427. Exelixis, Inc. has a twelve month low of $31.90 and a twelve month high of $49.62. The company has a market capitalization of $11.33 billion, a price-to-earnings ratio of 20.31, a P/E/G ratio of 0.79 and a beta of 0.32. The company has a 50-day moving average of $39.93 and a two-hundred day moving average of $40.73.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.10. The firm had revenue of $597.76 million during the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company’s revenue was up 10.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.47 EPS. Exelixis has set its FY 2025 guidance at EPS. On average, analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.

Institutional Investors Weigh In On Exelixis

Large investors have recently bought and sold shares of the business. Richardson Financial Services Inc. boosted its holdings in shares of Exelixis by 95.1% in the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after buying an additional 292 shares during the last quarter. Anchor Investment Management LLC lifted its holdings in Exelixis by 500.0% in the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 500 shares in the last quarter. Hemington Wealth Management increased its holdings in Exelixis by 211.3% in the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 522 shares during the last quarter. Root Financial Partners LLC bought a new position in Exelixis during the third quarter valued at approximately $28,000. Finally, Byrne Asset Management LLC grew its holdings in shares of Exelixis by 129.0% in the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 400 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Morgan Stanley increased their price target on Exelixis from $44.00 to $45.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. TD Cowen boosted their price objective on Exelixis from $44.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a report on Wednesday, October 8th. Royal Bank Of Canada restated a “sector perform” rating and issued a $45.00 price objective on shares of Exelixis in a research report on Tuesday, October 21st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Exelixis in a research note on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat.com, Exelixis currently has a consensus rating of “Moderate Buy” and an average target price of $45.45.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.